Latest Kidney Cancer News
Nivolumab treatment beyond disease progression results in reductions in tumor burden, study finds.
In a study, the 5-year risk of recurrence was 4.8%, 18.1%, and 46.3% for patients with low-, intermediate-, and high-risk disease.
Patients who used the drug had a 38% lower risk of dying from kidney cancer than non-users, meta-analysis shows.
Overall survival among patients receiving first-line targeted therapy for advanced renal cell carcinoma increased significantly from 2006 to 2012.
Study also finds associations between adiposity and 10 other cancers, particularly digestive and hormone-related malignancies.
The researchers found that patients treated with ABT had decreased progression-free survival compared with those not receiving ATB.
In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.
Added progression-free survival and prolonged overall survival possible, according to investigators.
Researchers develop a model to predict which patients are more likely to harbor brain metastases at cancer diagnosis.
Bone surgery should be considered in patients with solitary bone metastasis and no concomitant visceral metastases, according to investigators.
In a pilot study, metabolomic analyses of serum and urine showed a high level of predictive ability.
All patients with an SRM should be considered for a biopsy when the results may alter management.
The most common types of benign pathology were oncocytoma, angiomyolipoma, and complex cysts.
In a study, only 3 of 108 patients experienced complications, all of which were minor and required no hospitalization or further intervention.
In 2013, nearly one third of all minimally invasive radical nephrectomies were performed with robotic assistance.
Renal and Urology News Articles
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)